Here's the cleanest way to grasp it: mRNA medicine and RNA interference are opposites. An mRNA drug hands your cells a new instruction — "make this protein." An RNAi drug does the reverse — "stop making that one." Both are RNA-based, both ride similar delivery systems, but one adds a message and the other deletes one.
The way this actually works leans on a natural cellular system. Cells already have machinery that chops up RNA messages flagged as unwanted. An RNAi drug is a short, designed RNA strand whose sequence matches the message you want gone. When it finds its match, it recruits that machinery to cut the message up. No message, no protein. In plain terms, you're not editing the gene — you're intercepting its outgoing mail.
Think of it like spam filtering for the cell. The gene keeps sending out its message, but the RNAi drug acts as a filter that recognizes that specific message and shreds it before it's read. The gene itself is untouched, which is part of the appeal — the effect is potent but, in principle, reversible, because you're blocking the message rather than rewriting the source.
The patent record shows the modality at work on current targets. A 2026 published application, US20260159837A1 ("Coronavirus iRNA compositions and methods of use thereof"), describes interfering-RNA compositions aimed at coronavirus — using the silencing principle to knock down a viral target. It's a concrete, recent example of the same mechanism the field has spent years maturing.
Delivery, as with mRNA, is the hard part, which is why RNAi shares the lipid-nanoparticle and conjugate toolkit. Getting a fragile RNA strand into the right cells without it being destroyed first is the engineering challenge that gates the whole modality — and it's why so much adjacent patent activity is about carriers rather than the silencing RNA itself.
So add RNAi to your mental map of RNA medicine as the off-switch to mRNA's on-switch. One tells cells to build something new; the other tells them to stop building something harmful. The 2026 coronavirus application is a reminder that this silencing approach is still being pointed at fresh targets — quieter than the mRNA-vaccine headlines, but built on the same RNA foundation.